Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H23ClF2N4O5 |
Molecular Weight | 496.892 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CONC(=N)C1=CC=C(CNC(=O)[C@@H]2CCN2C(=O)[C@H](O)C3=CC(Cl)=CC(OC(F)F)=C3)C=C1
InChI
InChIKey=XSNMGLZVFNDDPW-ZWKOTPCHSA-N
InChI=1S/C22H23ClF2N4O5/c1-33-28-19(26)13-4-2-12(3-5-13)11-27-20(31)17-6-7-29(17)21(32)18(30)14-8-15(23)10-16(9-14)34-22(24)25/h2-5,8-10,17-18,22,30H,6-7,11H2,1H3,(H2,26,28)(H,27,31)/t17-,18+/m0/s1
Molecular Formula | C22H23ClF2N4O5 |
Molecular Weight | 496.892 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Atecegetran metoxil (more widely known as AZD0837), an anticoagulant and a prodrug, converted to a selective and reversible direct thrombin inhibitor (AR-H067637). Atecegetran metoxil participated in phase II clinical trials to prevent the stroke and systemic embolism in patients with non-valvular atrial fibrillation. The development of atecegetran metoxil was discontinued, due to a limitation identified in the long-term stability of the extended-release drug product.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19690349
150, 300, or 450 mg once daily or 200 mg twice daily
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 20:10:37 GMT 2023
by
admin
on
Fri Dec 15 20:10:37 GMT 2023
|
Record UNII |
4GU1D587JV
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB12507
Created by
admin on Fri Dec 15 20:10:37 GMT 2023 , Edited by admin on Fri Dec 15 20:10:37 GMT 2023
|
PRIMARY | |||
|
4GU1D587JV
Created by
admin on Fri Dec 15 20:10:37 GMT 2023 , Edited by admin on Fri Dec 15 20:10:37 GMT 2023
|
PRIMARY | |||
|
9961205
Created by
admin on Fri Dec 15 20:10:37 GMT 2023 , Edited by admin on Fri Dec 15 20:10:37 GMT 2023
|
PRIMARY | |||
|
C551586
Created by
admin on Fri Dec 15 20:10:37 GMT 2023 , Edited by admin on Fri Dec 15 20:10:37 GMT 2023
|
PRIMARY | |||
|
9282
Created by
admin on Fri Dec 15 20:10:37 GMT 2023 , Edited by admin on Fri Dec 15 20:10:37 GMT 2023
|
PRIMARY | |||
|
C166758
Created by
admin on Fri Dec 15 20:10:37 GMT 2023 , Edited by admin on Fri Dec 15 20:10:37 GMT 2023
|
PRIMARY | |||
|
DTXSID80963003
Created by
admin on Fri Dec 15 20:10:37 GMT 2023 , Edited by admin on Fri Dec 15 20:10:37 GMT 2023
|
PRIMARY | |||
|
100000141573
Created by
admin on Fri Dec 15 20:10:37 GMT 2023 , Edited by admin on Fri Dec 15 20:10:37 GMT 2023
|
PRIMARY | |||
|
SUB93456
Created by
admin on Fri Dec 15 20:10:37 GMT 2023 , Edited by admin on Fri Dec 15 20:10:37 GMT 2023
|
PRIMARY | |||
|
433937-93-0
Created by
admin on Fri Dec 15 20:10:37 GMT 2023 , Edited by admin on Fri Dec 15 20:10:37 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|